Two Californian firms, Gilead Sciences (Nasdaq: GILD) and Arcus Biosciences (NYSE: RCUS), have doubled down on their commitment to developing new therapies using the TIGIT pathway.
Recent research has shown the importance of TIGIT in regulating immune cell function in the tumor microenvironment, leading scientists to identify therapeutic potential in areas including lung cancer.
The major new agreement, building on work which began in 2020, will see Gilead pay $320 million to boost its ownership in Arcus to around a third.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze